Saeid Shahrabi

Saeid Shahrabi

Auto-generated profile, based on publicly available information

Saeid Shahrabi

Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
HHHabib Haybar
Habib Haybar
SSSaeid Shahrabi
Saeid Shahrabi
HRHadi Rezaeeyan
Hadi Rezaeeyan
RSReza Shirzad
Reza Shirzad
NNajmaldin Saki
Najmaldin Saki

19 June 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SSSaeid Shahrabi
Saeid Shahrabi
MMMohsen Maleknia
Mohsen Maleknia
YTYousef Tavakolifar
Yousef Tavakolifar
ZZZeinab Deris Zayeri
Zeinab Deris Zayeri
NNajmaldin Saki
Najmaldin Saki
Neutropenia is known as a clinical consequence in various genetic disorders and other neutropenia-inducing mutations (NIM) nonmalignant diseases. Leukemia development is now a major concern about the mortality of patients with congenital neutropenia. We searched the PubMed database and Google Scholar engine using English-language article (1980–2019) using the terms ‘Neutropenia,’ ‘Leukemia,’ ‘Mutation,’ and ‘Polymorphism.’ Patients with neutropenia have leukemia-related genetic abnormalities which are noticeable as mutations and chromosome abnormalities. The presence of mutations in patients with neutropenia can affect the biological function of neutrophils and increase the likelihood of leukemia progression, which can be important in the diagnosis and prognosis of patients. NIM can play an important role in leukemia development via enhancing intracellular signaling, apoptosis inhibition, and effects on transcription factors in patients with neutropenia. Therefore, the detection of genetic risk factors can be useful in prognosis, early diagnosis, and prevention of leukemia development.

1 November 2020 in Expert Review of Hematology
Verified
Journal Article
Closed access
EHElham Homaei Hadad
Elham Homaei Hadad
SPSeyed Mohammad Sadegh Pezeshki
Seyed Mohammad Sadegh Pezeshki
SSSaeid Shahrabi
Saeid Shahrabi
AMAmal Saki Malehi
Amal Saki Malehi
NNajmaldin Saki
Najmaldin Saki
Objective Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders that may occur after one or more mutations in hematopoietic progenitor cells. In this study, we will review the co-existence of mutations (especially dual mutations) in MPNs and its effect on the prognosis of patients. Methods To find relevant published papers, we systematically searched six major international indexing databases, namely PubMed/Medline, EmBase, Cochrane central, ISI web of science, and Scopus from Feb. 2000 until Jan. 2020. We included the following keywords in the analyzes: Myeloproliferative Disorders, Mutation, Co-existence of Mutations, Acute myeloid leukemia. Results Co-existence of several mutations in MPNs is mainly associated with a poor prognosis compared with the unimutated MPN disorders. There are several effective factors such as sequence of mutations, incidence of mutations in one cell or different cells, mutation, and MPN type. Conclusion and expert commentary It seems that monitoring the status of mutations in MPNs and recognizing the co-existence of mutations (especially dual mutations) in order to determine prognosis and possibility of progression to acute form of leukemia can lead to the prediction of prognosis in MPN patients as well as establishment of better and more reliable therapeutic strategies for patients.